ES2119268T3 - Procedimiento para fabricar ranitidina base de calidad farmaceutica. - Google Patents

Procedimiento para fabricar ranitidina base de calidad farmaceutica.

Info

Publication number
ES2119268T3
ES2119268T3 ES95107137T ES95107137T ES2119268T3 ES 2119268 T3 ES2119268 T3 ES 2119268T3 ES 95107137 T ES95107137 T ES 95107137T ES 95107137 T ES95107137 T ES 95107137T ES 2119268 T3 ES2119268 T3 ES 2119268T3
Authority
ES
Spain
Prior art keywords
ranitidine
manufacture
procedure
quality base
pharmaceutical quality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95107137T
Other languages
English (en)
Inventor
Jag Mohan Khanna
Naresh Kumar
Brij Khera
Purna Chandra Ray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/265,308 external-priority patent/US5696275A/en
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Application granted granted Critical
Publication of ES2119268T3 publication Critical patent/ES2119268T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN PROCESO PARA LA FABRICACION DE UNA BASE (N-[2-[[[5-(DIMETILAMINO)METIL]-2-FURANIL]METIL]TIO]ETIL-N''-METIL-2-NITRO-1,1ETENEDIAMINA) DE RANITIDINA DE GRADO FARMACEUTICO. ESTUDIOS FARMACOLOGICOS IN VITRO E IN VIVO Y ESTUDIOS DE TOXICIDAD AGUDA INDICAN QUE ESTA COMPOSICION ES TAN ACTIVA Y SEGURA COMO EL HIDROCLORURO DE RANITIDINA FORMA F2.
ES95107137T 1994-06-24 1995-05-11 Procedimiento para fabricar ranitidina base de calidad farmaceutica. Expired - Lifetime ES2119268T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/265,308 US5696275A (en) 1994-05-13 1994-06-24 Process for the manufacture of pharmaceutical grade ranitidine base

Publications (1)

Publication Number Publication Date
ES2119268T3 true ES2119268T3 (es) 1998-10-01

Family

ID=23009923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95107137T Expired - Lifetime ES2119268T3 (es) 1994-06-24 1995-05-11 Procedimiento para fabricar ranitidina base de calidad farmaceutica.

Country Status (3)

Country Link
EP (1) EP0697411B1 (es)
DE (1) DE69503196T2 (es)
ES (1) ES2119268T3 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4055699A (en) * 1998-06-17 2000-01-05 Russinsky Limited Ranitidine adduct
YU52598A (sh) * 1998-11-19 2001-05-28 D.D. Zdravlje- sektor za istraživanje i razvoj POSTUPAK ZA sintezu N-[2[[[5=[(DIALKILAMINO)METIL]-2= FURANIL]METIL]TIO]ETIL]-N'-ALKIL-2-NITRO 1,1 ALKENDIAMINA I NJIHOVIH HIDROHLORIDA
CN108017601B (zh) * 2017-12-28 2021-07-13 云鹏医药集团有限公司 一种精制雷尼替丁碱的方法
CN108727312B (zh) * 2018-08-03 2021-05-18 上海金城素智药业有限公司 雷尼替丁口服制剂治疗糜烂性食管炎的新适应症

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
EP0285681B1 (de) * 1987-04-06 1993-03-10 HEUMANN PHARMA GMBH & CO Verfahren zur Herstellung von Nitroethenderivaten

Also Published As

Publication number Publication date
EP0697411B1 (en) 1998-07-01
DE69503196D1 (de) 1998-08-06
EP0697411A1 (en) 1996-02-21
DE69503196T2 (de) 1999-02-18

Similar Documents

Publication Publication Date Title
EA200200571A1 (ru) Новая композиция и ее применение
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
DE60207198D1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
ITRM920155A1 (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
RS49907B (sr) Koncentrat delotvorne supstance sa formoterolom koji je duže upotrebljiv
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
SE9904508D0 (sv) New compounds
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
UA35604C2 (uk) Фармацевтична композиція з антидепресивною активністю
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
GEP20043162B (en) Derivatives of Isosorbid Mononitrate, Utilization as Vasodilator Agents with Reduced Tolerance
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
ES2119268T3 (es) Procedimiento para fabricar ranitidina base de calidad farmaceutica.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
BR0008657A (pt) Comprimidos deglutìveis com teor elevado den-acetilcisteì na e processo para a preparação dosmesmos
YU47338B (sh) Novo jedinjenje 4-fluoro-2-// (4-metoksi-2-piridinil)metil-/sulfinil/- 1h-benzimidazol i postupak za njegovo dobijanje
FR2767527B1 (fr) Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
PT858337E (pt) Composicao farmaceutica para o tratamento de doencas auto-imunes
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
ES534859A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquilsulfonilfenil)-2-amino-1,3-propandiol n-substituidos
SE9902387D0 (sv) New pharmaceutically active compounds
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 697411

Country of ref document: ES